Beginning 20 September, June Raine will be the new interim Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA).

June Raine will replace Ian Hudson, who will step down after 18 years with MHRA, including six years as chief executive. In addition to Ian Hudson, John Wilkinson, director of devices at MHRA, will step down at the end of October.

While working at MHRA’s predecessor Medicines Division since 1985 and at MHRA since 2003, June Raine has served as MHRA’s director of the Vigilance and Risk Management of Medicines division since 2006. Her experience also includes chairing the European Pharmacovigilance Risk Assessment Committee on behalf of the European Medicines Agency from 2012 to 2018.

Read full MHRA article.

Back to e-newsletter.